Journal of Biomolecular Research & Therapeutics

Impact of Biologic Drugs on Healthcare: Quality Convenience Accessibility

Jan Traub^* Department of Biomedical Engineering, Johns Hopkins University, Baltimore, United States of America
^*Correspondence: Jan Traub, Department of Biomedical Engineering, Johns Hopkins University, Baltimore, United States of America, Email:

Received: 29-Nov-2024, Manuscript No. BOM-24-28354; Editor assigned: 02-Dec-2024, Pre QC No. BOM-24-28354 (PQ); Reviewed: 16-Dec-2024, QC No. BOM-24-28354; Revised: 23-Dec-2024, Manuscript No. BOM-24-28354 (R); Published: 30-Dec-2024, DOI: 10.35248/2167-7956.24.13.418

Description

Protein-based biologic drugs, including monoclonal antibodies, hormones and therapeutic enzymes, have transformed the landscape of modern medicine. These drugs offer innovative treatment options for conditions ranging from autoimmune disorders to cancers. However, their complexity and sensitive nature present unique challenges in both product quality and user centricity. This article examines the impact of protein-based biologic drugs on product quality, with a focus on their influence on user experience and accessibility [1-3].

Unlike traditional small-molecule drugs, biologic drugs are derived from living organisms and involve large, complex proteins that are difficult to manufacture. The inherent complexity of their structure, coupled with the variability in production processes, can impact the quality of the final product. Ensuring the consistency of biologics is a major challenge for manufacturers, as even minor changes in the production environment, such as temperature fluctuations, can result in changes to the protein structure. These structural changes can, in turn, alter the drug’s efficacy and safety profile [4,5].

To address these challenges, stringent quality control measures are employed throughout the production process. Biologic drug manufacturers rely on advanced technologies such as High- Performance Liquid Chromatography (HPLC), mass spectrometry and advanced analytics to monitor protein integrity and purity. Furthermore, the development of biosimilars-drugs designed to be highly similar to approved biologics-has introduced another layer of complexity. While biosimilars offer the potential for cost savings, they must meet rigorous standards to demonstrate equivalent safety, efficacy and quality to the original biologic product [6,7].

Ensuring product quality throughout the drug's lifecycle is also critical. The shelf-life of biologics is often limited due to their sensitivity to environmental factors such as heat, light and pH. Maintaining the stability and efficacy of these drugs from production to administration involves the use of specialized packaging, cold chain logistics and advanced storage techniques. These considerations are integral to ensuring that patients receive drugs that are both safe and effective [8].

User centricity in the context of biologic drugs refers to the focus on the patient’s experience throughout the treatment journey, from drug administration to follow-up care. Biologics, especially those administered via injection or infusion, can present significant barriers for patients, including pain, inconvenience and discomfort. This is especially true for chronic conditions such as rheumatoid arthritis or Crohn’s disease, where long-term biologic therapy is required. As such, the design and delivery methods of biologics have become a key area of focus for improving user centricity [9].

Subcutaneous biologic injections have gained popularity over intravenous infusions due to their convenience and reduced time commitment for patients. Devices like pre-filled syringes, autoinjectors and wearable injection systems are enhancing the ease of administration and empowering patients to selfadminister their treatments at home. These innovations not only make it easier for patients to integrate biologic therapy into their daily lives but also contribute to better adherence to treatment regimens, which is essential for managing chronic conditions [10].

Moreover, patient support programs and digital health tools have become increasingly important in ensuring that patients can access and effectively use biologic drugs. For example, educational materials, online platforms and mobile apps can provide patients with instructions on proper drug administration, as well as offer reminders and track their progress. Such tools promote informed decision-making, reduce anxiety about treatment and ultimately improve patient outcomes.

Another aspect of user centricity is the affordability and accessibility of biologic drugs. Due to the high cost of production, biologics are often expensive, which can limit their availability, especially in low-and middle-income countries. Manufacturers and healthcare providers are therefore exploring ways to make these life-saving drugs more accessible. Initiatives such as the development of biosimilars, which can offer costeffective alternatives to original biologic products, are an important step in addressing this issue. Furthermore, governments and insurers are increasingly working to expand reimbursement schemes to ensure that biologic therapies are accessible to a broader range of patients.

Conclusion

Protein-based biologic drugs have revolutionized the treatment of many serious and chronic diseases. However, their complexity presents significant challenges in ensuring product quality and enhancing user centricity. Manufacturers must balance the need for consistent, high-quality products with the necessity of creating patient-friendly solutions that make treatment more accessible and less burdensome. Advances in biotechnology, improved drug delivery systems and a focus on patient education are essential in overcoming these challenges. By prioritizing both product quality and user-centric design, the healthcare industry can maximize the potential of biologic drugs, improving outcomes for patients worldwide.

References

1. Grega D, Kolar J. The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment. Value Health Reg Issues. 2024;40:13-18.

   [Google Scholar] [Crossref] [PubMed]  

2. Shah SA, Sohail M, Nakielski P, Rinoldi C, Zargarian SS, Kosik-Kozioł A, Integrating Micro-and Nanostructured Platforms and Biological Drugs to Enhance Biomaterial-Based Bone Regeneration Strategies. Biomacromolecules. 2024;26(1):140-162.

   [Crossref] [Google Scholar] [PubMed]      

3. Adler M, Allmendinger A. Filling unit operation for biological drug products: challenges and considerations. J Pharm Sci. 2024;113(2):332-344.

   [Crossref] [Google Scholar] [PubMed]  

4. Du Y, Song J, Lu L, Yeung E, Givand J, Procopio A, et al. Design of a Reciprocal Injection Device for Stability Studies of Parenteral Biological Drug Products. J Pharm Sci. 2024;113(5):1330-1338.

   [Crossref] [Google Scholar] [PubMed]   

5. Stevenson J, Poker R, Schoss J, Campbell M, Everitt C, Holly B, et al. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design. Adv Drug Deliv Rev. 2024;115322.

   [Crossref] [Google Scholar] [PubMed]   

6. Hussain AB, Hampton PJ. Improving the Accuracy of Biologic Drug Survival Data: The Increasing Prevalence of Off-Label Dosing Must Be Considered when Reporting Drug Effectiveness and Safety. J Invest Dermatol. 2023;143(11):2096-2098.

   [Crossref] [Google Scholar] [PubMed]  

7. Ferreira LB, Smith AJ, Smith JR. Biologic drugs for the treatment of noninfectious uveitis. Asia Pac J Ophthalmol. 2021;10(1):63-73.

   [Crossref] [Google Scholar] [PubMed]   

8. Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, et al. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021;11(4):941-960.

   [Crossref] [Google Scholar] [PubMed]  

9. Phyo P, Zhao X, Templeton AC, Xu W, Cheung JK, Su Y. Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy. Adv Drug Deliv Rev. 2021;174:1-29.

   [Crossref] [Google Scholar] [PubMed]    

10. Muralidhara BK, Wong M. Critical considerations in the formulation development of parenteral biologic drugs. Drug Discov Today. 2020;25(3):574-581.

    [Crossref] [Google Scholar] [PubMed]